Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a report released on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently weighed in on TRVN. JMP Securities reaffirmed a “market outperform” rating and set a $2.00 price objective on shares of Trevena in a research report on Friday, March 31st. HC Wainwright cut their price target on Trevena from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, March 31st.

Trevena Stock Up 393.7 %

Shares of NASDAQ TRVN opened at $3.11 on Tuesday. Trevena has a 12-month low of $0.58 and a 12-month high of $12.22. The stock has a market cap of $29.82 million, a PE ratio of -0.40 and a beta of 2.05. The company has a current ratio of 4.70, a quick ratio of 4.59 and a debt-to-equity ratio of 0.86. The company has a 50-day moving average of $0.82 and a 200 day moving average of $1.42.

Trevena (NASDAQ:TRVN – Get Rating) last posted its earnings results on Thursday, March 30th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter. As a group, sell-side analysts predict that Trevena will post -3.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Armistice Capital LLC purchased a new position in shares of Trevena in the 4th quarter valued at about $919,000. Dimensional Fund Advisors LP acquired a new stake in shares of Trevena in the 4th quarter valued at about $40,000. Renaissance Technologies LLC boosted its position in shares of Trevena by 10.2% in the 3rd quarter. Renaissance Technologies LLC now owns 1,096,100 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 101,900 shares during the period. Virtu Financial LLC boosted its position in shares of Trevena by 72.7% in the 3rd quarter. Virtu Financial LLC now owns 290,480 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 122,242 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Trevena in the 2nd quarter valued at about $25,000.

About Trevena

(Get Rating)

Trevena, Inc is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A.